ClinicalTrials.gg
RecruitingNCT07539285Updated Apr 20, 2026

A Study of HDM2024 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of HDM2024 in Advanced Solid Tumors, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are:

  • Is the drug safe and tolerable ?
  • Does the drug exhibit antitumor activity ?

Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.

Read the detailed description

Target population are patients with advanced solid tumors .

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • ADC
  • advanced solid tumors
  • EGFR
  • HER3
03

In context

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Participants who voluntarily participate in this study and sign the written Form (ICF) after being fully informed.
  • 2. Male or female participants aged 18 to 75 years (inclusive).
  • 3. Participants with or cytologically confirmed locally advanced unresectable or solid tumors who have experienced disease progression on or after standard therapy , or are intolerant to standard therapy, or for whom no effective standard of care is available.
  • 4. Participants who are able to provide fresh or during the screening period. Tumor tissue will be collected for biomarker testing at a central laboratory, including immunohistochemistry for EGFR and HER3 .
  • 5. Performance Status (ECOG PS) of 0 or 1 .
  • 6. ≥3 months.
  • 7. According to v1.1, the participant must have at least one .
  • 8. Participants with good organ function as demonstrated by screening laboratory test results.
  • 9. The fertile participants agreed to take effective measures during the study and after its conclusion; and must have a negative serum human chorionic gonadotropin (HCG) test within 7 days before dosing.
  • 10. Participants should be willing and able to complete regular visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • 1. Participants who have previously received ADC containing exatecan , or an ADC primarily directed against EGFR and/or HER3.
  • 2. Participants who have received the following treatments:

    1. Participants who have undergone major surgery within 4 weeks before the first dose;
    2. Participants who have received radiotherapy involving the bone marrow or extensive radiotherapy within 4 weeks before the first dose; or local radiotherapy within 2 weeks before the first dose;
    3. Participants who are receiving continuous systemic therapy ; low-dose corticosteroids are permitted if the dose of systemic corticosteroids has been stable for 4 weeks;
    4. Participants who have received anti-tumor treatments within 4 weeks before the first dose, or are still within 5 half-lives of the last dose of the most recent anticancer therapy (whichever is longer). Traditional Chinese medicines with approved anticancer indications within 2 weeks prior to the first administration of study drug.
  • 3. Participants with other malignant tumor within the past 5 years, other than the tumor treated in this study, with the exception of locally cured tumors .
  • 4. Participants with related AEs (except for alopecia and ≤ Grade 2 sensory neuropathy) caused by previous treatment that have not recovered to ≤ Grade 1 or baseline level.
  • 5. Participants with known weight loss of >10% within 2 months before the first dose of the study drug or other indicators showing severe malnutrition.
  • 6. Participants with serious complications or medical histories involving important organs.
  • 7. Participants with known active central nervous system (CNS) .
  • 8. Participants with any of the cardiovascular/cerebrovascular disorders, symptoms, or manifestations.
  • 9. Participants with the following conditions will be excluded at screening: active syphilis, history of (HIV) infection, active virus (HBV) or active virus (HCV), with the exception of asymptomatic chronic hepatitis B or C virus carriers.
  • 10. Participants with a history of interstitial pneumonia or other moderate to severe lung disorders that seriously affect lung function.
  • 11. Participants with severe infection during the screening period.
  • 12. Participants with other diseases that may affect the efficacy and safety of the study drug.
  • 13. Participants with uncontrolled pericardial effusion, uncontrolled pleural effusion, or moderate or greater ascites during the screening period.
  • 14. Participants with unstable thrombotic events requiring therapeutic intervention within 6 months before screening; however, thrombosis related to infusion devices is not included.
  • 15. Participants who have received a within 30 days before the first dose, or plan to receive a live vaccine during the study period.
  • 16. Participants who have received strong inhibitors and inducers therapy within 1 week before dosing, or are expected to require long-term use of strong CYP3A4 inhibitors and inducers during the study intervention and within 30 days after the last dose .
  • 17. Participants with history of solid organ transplant.
  • 18. Participants with known or suspected history of severe allergy to any component of the study drug or its analogues.
  • 19. Pregnant and lactating women.
  • 20. Participants who are deemed unsuitable for this study (e.g., poor compliance, etc.) by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    HDM2024

    HDM2024 ( the antibody-drug conjugate (ADC) drug targeting epidermal growth factor receptor (EGFR) \& human epidermal growth factor receptor 3 (HER3) )

    Drug: HDM2024

Interventions

  • DrugHDM2024

    ADC drug targeting EGFR and HER3

06

What researchers measure

Primary outcomes

  1. Maximal tolerance dose (MTD) of HDM2024

    The MTD is defined as the dose level at which the estimated toxicity probability is closest to the target toxicity rate during the Dose-limiting toxicity (DLT) observation period of the dose escalation stage.

    Time frame: DLT will be evaluated on 21 days of observation period

  2. Determination of the Recommended Phase 2 dose (RP2D)

    Time frame: Approximately 1 years

  3. Incidence and severity of Treatment-Emergent Adverse Events

    Incidence rates of adverse events (AE), serious adverse events (SAE)per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v6.0.

    Time frame: Approximately 1 years

Secondary outcomes

  1. Time to peak (Tmax) of HDM2024

    Tmax of HDM2024, total antibody, and exatecan will be measured

    Time frame: Approximately 1 years

  2. Half-life time (t1/2) of HDM2024

    t1/2 of HDM2024, total antibody, and exatecan will be measured

    Time frame: Approximately 1year

  3. Peak Plasma Concentration (Cmax) of HDM2024

    Cmax of HDM2024, total antibody, and exatecan will be measured

    Time frame: Approximately 1 year

  4. Area under the plasma concentration versus time curve (AUC) of HDM2024

    AUC of HDM2024, total antibody, and exatecan will be measured

    Time frame: approximately 1 year

  5. Objective response rate (ORR)

    ORR assessed based on RECIST v1.1 criterion

    Time frame: Approximately 1 year

  6. Disease control rate (DCR)

    DCR assessed based on RECIST v1.1 criterion

    Time frame: Approximately 1 year

  7. Progression-free survival (PFS)

    PFS assessed based on RECIST v1.1 criterion

    Time frame: Approximately 1year

  8. Overall survival (OS)

    OS of 6-months and 12-months

    Time frame: Approximately 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 20, 2026
StartEst.
Apr 10, 2026
Primary completionEst.
Apr 15, 2027
CompletionEst.
Dec 28, 2028
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07539285
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 10, 2026 (estimated)
Primary completion
Apr 15, 2027 (estimated)
Completion
Dec 28, 2028 (estimated)
Last update
Apr 20, 2026

Study contacts

Zhou Caicun
Contact
caicunzhoudr@163.com
+8613301825532

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion